CAMBRIDGE, Mass.--(BUSINESS WIRE)--Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation radiopharmaceuticals for the treatment of cancer, today announced interim data from Part 3 of its Phase 2 CONVERGE-01 study of Ac-225 rosopatamab tetraxetan (CONV01-α) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Lu-177-PSMA radioligand therapy (Lu-PSMA). In the study, CONV01-α demonstrated promising anti-tumor act